Palantir Faces a Pincer Movement: Regulatory Heat in the UK Meets Existential AI Questions
Published on 07/27/2026 at 13:12 | Redaktion boerse-global.de
Palantir’s stock is caught between two very different kinds of pressure. On one side, a British data watchdog has cast a shadow over the company’s health-care operations, raising uncomfortable questions about the reliability of its NHS-related claims. On the other, the broader narrative that once made Palantir a darling of the AI boom—its unique ability to transform messy datasets into actionable intelligence—is being challenged by the very large language models the company helped popularize. The result is a stock that closed Friday at €107.90, down 0.5% on the day and 31.33% lower since the start of the year.
The most acute blow came midweek. On Wednesday, Palantir’s shares tumbled 6.1%—the steepest single-day decline of the week—after the Financial Times reported that Britain’s National Health Service had attached caveats to positive findings about Palantir’s health-data platform. A UK statistical review had concluded that the data presented could not demonstrate a causal link. For a company whose government contracts are a cornerstone of its bull case, the timing could hardly have been worse, coming just ahead of the next quarterly earnings report due in the first days of August.
That regulatory headache is compounding a deeper strategic anxiety. Palantir’s core pitch—that no one else can build the “ontologies” that turn chaotic government and corporate data into decision-ready tools—is facing an unexpected threat from the AI labs it once rode alongside. Anthropic recently published a blog post detailing its expanding data-analysis capabilities, and UBS analysts responded bluntly, warning that the development sounds “not good” for software firms like Palantir and Snowflake. Even Snowflake, typically described as a Palantir partner, acknowledged overlaps between the capabilities of large AI models and those of traditional data specialists.
The concern moved from abstract to concrete at Palantir’s own AIPCon 10 conference in San Francisco, where a customer openly said he was weighing whether to build a parallel open-source graph database—or simply switch to OpenAI and Anthropic. That kind of public wavering from a paying client is the sort of signal that turns market chatter into a tangible risk.
Should investors sell immediately? Or is it worth buying Palantir?
CEO Alex Karp is pushing back hard. In an interview with CNBC, he called the idea that large language models could replace Palantir’s enterprise product a “complete farce.” His argument: Palantir’s AIP platform sells outcomes, not tokens, wrapped in an ontology and delivered through boot camps that demonstrate return on investment within weeks. But the stock chart tells a more ambiguous story. Palantir now trades roughly 17% below its 200-day moving average, a gap that suggests an intact downtrend even after a 10% recovery over the past month. The relative strength index sits at 45, signaling neutral momentum, while annualized volatility of around 49% underscores just how violently the stock can swing in either direction.
The bear case has gained a prominent voice. Hedge-fund manager Michael Burry, famous for betting against the US housing market before the 2008 financial crisis, has been shorting Palantir for months. In late June, he disclosed covering half his short position at $107.15 while holding on to put options. A trader with that track record adds real weight to the cautious camp. Yet analysts remain broadly optimistic: the average price target stands at €160.97, implying upside of nearly 47% from current levels. Such a wide gap between market price and analyst expectations is rare for Palantir, and it encapsulates the central debate—are analysts lagging behind a slowing growth story, or is the market overreacting to noise from Anthropic and OpenAI?
The company’s fundamentals in defense and government work, including high-profile military modernization projects, remain intact and continue to underpin the bull thesis. But that alone is no longer enough to quiet doubts about the commercial moat. The first-quarter numbers were strong—revenue grew 85%, gross margin improved from 80% to 87%, US commercial revenue jumped 133% to $595 million, and US government revenue rose 84% to $687 million—yet the stock still fell. The sell-off in Palantir is not an isolated phenomenon: the broader enterprise software sector has been under pressure as investors rotate away from SaaS names amid new model releases from Anthropic and OpenAI. Recent quarterly reports from IBM and ServiceNow have only amplified the selling wave.
Palantir at a turning point? This analysis reveals what investors need to know now.
Palantir’s next earnings release, expected in early August, will be the most closely watched in months. The numbers themselves may be strong, but the stock’s vulnerability lies in whether revenue growth can absorb the twin shocks of valuation concerns and the new questions surrounding the NHS data. With a 14-day RSI of 42.6 and volatility still elevated, the market is not yet ready to pick a side.
Ad
Palantir Stock: New Analysis - 27 July
Fresh Palantir information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
